AB AB Science S.A.
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer's disease, and indolent systemic mastocytosis, as well as in Phase 2 trial for mast cell activation syndrome and sickle cell disease. It also develops AB8939, a microtubule destabilizer in Phase 1 trial for the treatment of acute myeloid leukemia; and AB12319 in preclinical trial to treat sarcoma and solid tumors. In addition, the company markets its masitinib under the Masivet brand for the treatment of mast cell tumors in dogs in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About AB Science (EPA: AB)
›
AB Science (EPA: AB) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 33 employees.
The shares were at 0.5680 EUR on 19 November 2026, down 50.6% over 52 weeks. Its 52-week range is 0.4880 EUR to 1.610 EUR: the price is 64.7% below the high and 16.4% above the low.
Its market capitalisation is 54.35M EUR.
AB Science reports return on equity of 9.1% and revenue down 3.3% year over year.
Its debt exceeds its cash by 11.17M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.